Gene therapy for lung cancer

Masafumi Kataoka, Toshiyoshi Fujiwara, Noriaki Tanaka

Research output: Contribution to journalArticle

Abstract

Surgical resection is so far the most reliable therapy for localized non-small-cell lung cancer (NSCLC). Although the combination of several modalities such as chemotherapy or radiotherapy is used to treat advanced or recurrent disease, the results have not been satisfactory. A new therapeutic strategy is thus required to improve lung cancer treatment. Gene therapy is one such new therapeutic strategy. Several clinical trials of gene therapy protocols have been conducted and patient eligibility and being efficacy are evaluated. Representative studies of gene therapy for lung cancer and an interim report on a clinical trial using adenovirus vector expressing wild-type p53 in non-small cell lung cancer in Japan are introduced in this paper. Problems encountered and future regimens are also discussed.

Original languageEnglish
Pages (from-to)244-249
Number of pages6
JournalNippon Geka Gakkai zasshi
Volume103
Issue number2
Publication statusPublished - 2002

Fingerprint

Genetic Therapy
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Clinical Trials
Therapeutics
Adenoviridae
Japan
Radiotherapy
Drug Therapy

Cite this

Kataoka, M., Fujiwara, T., & Tanaka, N. (2002). Gene therapy for lung cancer. Nippon Geka Gakkai zasshi, 103(2), 244-249.

Gene therapy for lung cancer. / Kataoka, Masafumi; Fujiwara, Toshiyoshi; Tanaka, Noriaki.

In: Nippon Geka Gakkai zasshi, Vol. 103, No. 2, 2002, p. 244-249.

Research output: Contribution to journalArticle

Kataoka, M, Fujiwara, T & Tanaka, N 2002, 'Gene therapy for lung cancer', Nippon Geka Gakkai zasshi, vol. 103, no. 2, pp. 244-249.
Kataoka M, Fujiwara T, Tanaka N. Gene therapy for lung cancer. Nippon Geka Gakkai zasshi. 2002;103(2):244-249.
Kataoka, Masafumi ; Fujiwara, Toshiyoshi ; Tanaka, Noriaki. / Gene therapy for lung cancer. In: Nippon Geka Gakkai zasshi. 2002 ; Vol. 103, No. 2. pp. 244-249.
@article{8e4452e878994ad19a51b85bcf08707d,
title = "Gene therapy for lung cancer",
abstract = "Surgical resection is so far the most reliable therapy for localized non-small-cell lung cancer (NSCLC). Although the combination of several modalities such as chemotherapy or radiotherapy is used to treat advanced or recurrent disease, the results have not been satisfactory. A new therapeutic strategy is thus required to improve lung cancer treatment. Gene therapy is one such new therapeutic strategy. Several clinical trials of gene therapy protocols have been conducted and patient eligibility and being efficacy are evaluated. Representative studies of gene therapy for lung cancer and an interim report on a clinical trial using adenovirus vector expressing wild-type p53 in non-small cell lung cancer in Japan are introduced in this paper. Problems encountered and future regimens are also discussed.",
author = "Masafumi Kataoka and Toshiyoshi Fujiwara and Noriaki Tanaka",
year = "2002",
language = "English",
volume = "103",
pages = "244--249",
journal = "Nihon Geka Gakkai zasshi",
issn = "0301-4894",
publisher = "Nihon Geka Gakkai",
number = "2",

}

TY - JOUR

T1 - Gene therapy for lung cancer

AU - Kataoka, Masafumi

AU - Fujiwara, Toshiyoshi

AU - Tanaka, Noriaki

PY - 2002

Y1 - 2002

N2 - Surgical resection is so far the most reliable therapy for localized non-small-cell lung cancer (NSCLC). Although the combination of several modalities such as chemotherapy or radiotherapy is used to treat advanced or recurrent disease, the results have not been satisfactory. A new therapeutic strategy is thus required to improve lung cancer treatment. Gene therapy is one such new therapeutic strategy. Several clinical trials of gene therapy protocols have been conducted and patient eligibility and being efficacy are evaluated. Representative studies of gene therapy for lung cancer and an interim report on a clinical trial using adenovirus vector expressing wild-type p53 in non-small cell lung cancer in Japan are introduced in this paper. Problems encountered and future regimens are also discussed.

AB - Surgical resection is so far the most reliable therapy for localized non-small-cell lung cancer (NSCLC). Although the combination of several modalities such as chemotherapy or radiotherapy is used to treat advanced or recurrent disease, the results have not been satisfactory. A new therapeutic strategy is thus required to improve lung cancer treatment. Gene therapy is one such new therapeutic strategy. Several clinical trials of gene therapy protocols have been conducted and patient eligibility and being efficacy are evaluated. Representative studies of gene therapy for lung cancer and an interim report on a clinical trial using adenovirus vector expressing wild-type p53 in non-small cell lung cancer in Japan are introduced in this paper. Problems encountered and future regimens are also discussed.

UR - http://www.scopus.com/inward/record.url?scp=0036484495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036484495&partnerID=8YFLogxK

M3 - Article

C2 - 11904988

AN - SCOPUS:0036484495

VL - 103

SP - 244

EP - 249

JO - Nihon Geka Gakkai zasshi

JF - Nihon Geka Gakkai zasshi

SN - 0301-4894

IS - 2

ER -